Huntington's disease (HD) is a neurodegenerative disorder caused by a CAG trinucleotide repeat expansion in the huntingtin (HTT) gene. Disease pathogenesis derives, at least in part, from the long polyglutamine tract encoded by mutant huntingtin. Therefore, considerable effort has been dedicated to the development of therapeutic strategies that significantly reduce expression of the mutant huntingtin 
INTRODUCTION
The expansion of CAG trinucleotide repeats leads to at least nine autosomal dominant neurodegenerative diseases (1, 2) . Among them, Huntington's disease (HD), characterized by progressive motor, cognitive, and psychiatric abnormalities leading to death 15-20 years after clinical onset is the most common (3) (4) (5) . HD is caused by an expansion of the CAG repeat in the first exon of the HTT gene (6); disease inevitably results in individuals with 40 or more triplets, and may occur with as few as 36 triplets (and perhaps fewer) (7, 8) . The CAG repeat is translated into a polyglutamine tract (polyQ) within the huntingtin protein (HTT). Most investigators have concluded that toxicity of the expanded polyglutamine tract is the primary pathogenic mechanism in HD. Recently, it was shown that CAG repeats, including at the HD locus, can be translated into other homopolymeric tracts, including polyalanine and polyserine, through repeat-associated non-ATG (RAN) translation (9) .
In addition, mutant HTT RNA itself may be toxic (10) (11) (12) , suggesting that both RNA and protein gain-of-function contribute to the disease pathogenesis.
If both expanded HTT protein and transcript are neurotoxic, then the most direct therapeutic approach, aside from altering genomic DNA, is to use knockdown strategies to prevent protein expression and degrade expanded transcripts or block their toxicity. While ideally suppression is specific for the products of the expanded allele, the current consensus is that bi-allelic approaches may be successful as long as the level of normal HTT remains above the 30% threshold required for normal cell function (13) (14) (15) . Multiple strategies are under investigation, such as zinc finger peptides target double-stranded DNA to prevent transcription, therefore reducing both protein and RNA expression (16) , or peptides that bind to expanded polyglutamine to block its toxic function (17) . However, most mutant HTT knockdown strategies are single-nucleotide polymorphisms (SNPs) in HTT; the mutant HTT gene contains specific SNPs in 75-85% of HD patients, and targeting these SNPs with one of a pool of siRNAs or ASOs could provide allele-specific knockdown of HTT expression (23) (24) (25) (26) (27) . A second approach to allelic specificity employs siRNAs or ASOs that target the expanded CAG repeat. Indeed, CAG repeat-targeting siRNAs are effective at reducing the expression of mutant HTT mRNA with at least partial allelic selectivity in vitro (28) (29) (30) (31) (32) (33) (34) . However, implementation of siRNA-based silencing in vivo faces a several major obstacles, including the challenge of efficient delivery into the CNS, the relatively low stability of siRNAs, potential off-target effects, and the risk of activation of the immune system (35) . Compared to siRNA, ASOs have a major advantage in flexibility, as modifications can enhance their stability, RNA affinity, cellular uptake and biodistribution. ASOs such as gapmers [chimeric ASOs consisting of a DNA sequence with flanking locked nucleic acids (LNA) or 2'-O-Methoxyethyl (MOE) nucleic acids] can be used for RNase H-dependent degradation of targeted transcripts, an approach used to degrade CUG repeats in mouse models (36, 37) .
However, a number of CAG repeat loci, including the HD locus, contain antisense transcripts spanning the repeat region (38) (39) (40) , and it is possible that targeted degradation of sense transcripts may trigger an upregulation of CUG repeat-containing antisense transcripts with potential neurotoxic effects (41) (42) (43) (44) ). An alternative is to use ASOs that sterically block RNA translation and potentially RNA-mediated neurotoxicity without leading to transcript degradation. Such ASOs include peptide nucleic acids (PNAs), LNAs, chemically modified single-stranded RNAs (ssRNAs), and phosphorodiamidate morpholino oligonucleotides (PMOs).
Indeed, selective inhibition of the mutant HTT allele by PNA and LNA ASOs targeting the CAG repeat of the HTT transcript has been demonstrated (30, 31, (45) (46) (47) .
Chemically modified ssRNA has also been successfully applied to specifically silence expanded HTT expression both in vitro and in vivo (48) .
Here we examine the potential of PMOs in HD therapeutics. PMOs have advantages over other ASOs in therapeutic applications: the absence of an electrical charge, the lack of dependence on the activity of RNase H or other catalytic proteins 5 (49) (50) (51) , water solubility, stability, lack of non-specific toxicity even at high concentrations, and the capacity for extensive modifications. PMOs have shown great promise when injected peripherally, including preventing sequestration of muscleblind-like protein 1 (MBNL1) in myotonic dystrophy 1 (DM1) (52) and inducing targeted exon skipping in Duchenne muscular dystrophy (DMD) (53) (54) (55) (56) (57) (58) .
PMOs also can alter brain processes, such as reducing the anxiolytic effect of estrogen following a direct delivery into rat dorsal raphe nucleus (59), increasing survival of postnatal spinal muscular atrophy (SMA) mice (60) (61) (62) , and modulating feeding behavior in rats (63) .
In this study we designed multiple PMOs targeted to the HTT CAG repeat region and to the region flanking the HTT repeat. The effectiveness and allelic selectivity of the PMOs were examined in HD-patient derived fibroblast lines with repeat expansions of 44, 77 or 109 CAG triplets and in two HD mouse models, N171-82Q transgenic and Hdh Q7/Q150 knock-in mice. The effect on ameliorating neurotoxicity was examined in a neuroblastoma cell line. Our data demonstrate that PMOs can significantly decrease HTT protein expression without decreasing transcript level, with target selectivity and knock-down efficacy determined by PMO sequence and concentration, and by target CAG repeat length.
RESULTS
The specificity and effectiveness of a PMO depend on its sequence and concentration, as well as on the length of the targeted CAG repeat.
Based on the use of PMOs to ameliorate the toxicity of the CUG repeat expansion within the DMPK transcript associated with myotonic dystrophy 1 (DM1) (52), we synthesized three CAG repeat-targeting PMOs, CTG22, CTG25 and CTG28, respectively ( Fig. 1) Fig. 3) , indicating that increasing the length of the PMO CTG increases selectivity for long targeted repeats.
During the course of this study it was reported that a PMO consisting of 7 CTG triplets selectively decreased the expression of mutant HTT in HD-patient derived fibroblasts (30) . We therefore examined the effect of a similar PMO, CTG22 (7 CTG triplets and an additional C) in more detail. We found that, like CTG25, total ( Fig. 4A and C) and mutant ( Fig. 4B and C) levels of HTT in all three HD cell lines were significantly reduced by CTG22 treatment (Fig. 4A and C) ; however, no significant discrimination between normal and mutant HTT was observed in any of the lines.
These results demonstrate that as CTG repeat length becomes shorter, HTT expression increases but allelic selectivity decreases.
Taken together, we conclude that the allelic specificity and effectiveness of a repeat-targeting PMO depends on the length of the PMO repeat, the concentration of the PMO, and the length of the repeat in the targeted gene. (Fig. 5C ). Since AR and RAI1 are expressed at low levels in HD patient-derived fibroblasts, we tested the effect of these CAG repeat-targeting PMOs on the endogenous levels of both proteins in the SH-SY5Y neuroblastoma cell line, and we observed no significant reduction (Fig. 5D ). Representative western blot images for Figure 5 are shown in Figure S2 .
The data suggest that the off-target effect of repeat-targeting PMOs on endogenous genes is dependent on the sequence of the PMO and possibly the sequence flanking the repeat and subsequent tertiary structure of each repeat locus, as the length of the repeat in the endogenous control genes examined is not directly correlated to the off-target effect of the PMO.
Non-CAG repeat-targeting PMOs reduce HTT levels with high target selectivity
In addition to targeting the CAG repeat region in HTT RNA, targeting other regions may also be a feasible therapeutic approach if levels of normal HTT remain sufficient to support normal cell function (13, 18) . We therefore designed two non-CAG repeat-targeting PMOs, HTTex1a and HTTex1b ( 
RNA levels of HTT, HTTAS_v1 and control genes are not affected by PMOs
Since PMOs are designed to sterically block RNA translation through complementary binding with target RNA, PMO activity should not lead to degradation of targeted transcripts (49) . To confirm this, we analyzed HTT RNA levels, as well as the RNA levels of four endogenous control genes including ataxin 1 (ATXN)1, ATXN3, TBP
and atrophin-1 (ATN1) after treatment with each of the five PMOs. As expected, no significant effect on the levels of transcripts was observed (Fig. 7A ). Since CTG22
was the most effective at reducing overall HTT levels ( Fig. 4) , we used this PMO to determine if PMO-HTT transcript hybridization affects levels of the antisense transcript at the HD locus, HTTAS_v1 (38) . Our results indicate that neither the levels of sense HTT nor HTTAS_v1 are significantly changed following introduction of the PMO (Fig. 7B ). In addition, we observed that modulating the levels of the endoribonuclease dicer (DICER1) in HD cell line 19/109 transfected with PMO CTG22 has no significant effect on the levels of HTT (Fig. S3 ). Taken together, our experiments further confirm that PMO suppression of target expression does not involve degradation of either the targeted transcript or endogenous control genes.
PMOs show minimal cytotoxicity
Any ASO-based strategy to lower HTT expression must be evaluated for non-specific cell toxicity. Unlike other ASOs, PMOs typically do not have cytotoxic effects. We confirmed that this general rule extended to our PMOs, as we were unable to detect PMOs can diffuse into cytoplasm and nucleus in neurons. We transfected a FITC-labeled control (Ctrl) PMO into mouse primary cortical neurons. Interestingly, we detected a much higher level of PMO release from neuronal endosomes than from fibroblast endosomes (Fig. 9) . This finding confirms cell-type specific effect of PMOs, and provides a potential mechanistic explanation for cell-type specificity.
CTG25 and CTG28 inhibit mutant HTT expression in vivo
Since CTG25 reduced mutant HTT expression and rescued mutant HTT toxicity in vitro, we next examined the effect of CTG25 on HTT expression in vivo. We selected the N171-82Q transgenic HD mouse model for this experiment (68) , as the repeat size in the model resembles that in HD 20/77 fibroblasts, in which PMO CTG25 was the most effective ( Fig. 2A) . A single, low-dose (100 µg) standard control (Ctrl) or CTG25 PMO was injected into the right lateral ventricle of six-week-old N171-82Q
mice. The expression of the mutant HTT transgenic fragment in the frontal cortex was assessed two weeks post-injection. CTG25 was effective in reducing N171-82Q transgenic protein expression in the frontal cortex (Fig. 10A ) without significant effect on the levels of endogenous normal HTT and control proteins containing polyglutamine repeats (Fig. 10B) . The decrease of N171-82Q protein level in both ipsilateral and contralateral cortex suggests an efficient distribution of the PMO in vivo.
To further investigate the long-term efficacy and safety of PMOs, we also tested the effect of a repeat-targeting PMO in the Hdh Q7/Q150 knock-in HD mouse model, which has both normal and mutant HTT expression at endogenous levels (69) (70) (71) . We chose to use PMO CTG28 in this model based on its strong selectivity for expanded alleles in HD fibroblasts harboring 109 CAG repeats. Three successive, low-dose (100 µg) treatments of either Ctrl or CTG28 PMO were injected into the right lateral ventricle of six-month-old Hdh Q7/Q150 knock-in mice at six, eight, and ten months of age. At the age of twelve months, mice were assessed in the tail suspension test, which has been used to measure depressive-like behavior of YAC128 HD mice (72) , and the expression of HTT in various brain regions associated with the disease pathology was also assessed. No loss of body weight was observed in mice with CTG28 injections, suggesting that PMO CTG28 does not induce systemic deleterious effect (Fig. S4 ). CTG28 was effective in inhibiting the expression of mutant HTT (Fig.   10C , upper mouse HTT band) in the ipsilateral frontal cortex, ipsilateral striatum and cerebellum without affecting the levels of normal HTT (Fig. 10C , lower mouse HTT band) or control proteins containing polyglutamine repeats (Fig. 10D ). These data suggest that CTG28 exhibits efficient distribution in the brain, good efficacy in reduction of mutant HTT, and little off-target effect in vivo. Representative western blot images for the data quantified in Figure 10 are shown in Figure S2 . Promisingly, preliminary evidence also suggests that CTG28 improves the behavioral phenotype of Hdh Q7/Q150 HD mice (Fig. 10E ). Mice injected with CTG28 showed decreased immobility, increased latency to immobility and increased escape attempts compared to mice with Ctrl injections in the tail suspension test, an assay generally interpreted as a test of depressive-like phenotype (72) . The ability of PMOs to reduce target expression depends on their ability to enter cells through endocytosis and to be efficiently released from endosomes/lysosomes (73) . Our results show that PMOs have a wider intracellular distribution in neurons, and therefore their selectivity and effectiveness may be higher when delivered to neuronal cells than to fibroblasts (Fig. 9 ). This suggests that, while the endogenous levels of normal and expanded HTT in fibroblasts serve as a useful model for an initial evaluation of an ASO (74), they may not be fully informative when it comes to specificity and effectiveness of an ASO in neurons.
DISCUSSION
Our second and most important finding is that repeat-targeting PMOs are capable of significantly and selectively reducing mutant HTT expression in two different HD mouse models and that a safe reduction in one of the models is also accompanied by a preliminary improvement in phenotype. A single, low-dose intracerebroventricular (ICV) injection of CTG25 in N171-82Q transgenic HD mice selectively and significantly reduced the levels of mutant HTT in the frontal cortex without a significant effect on endogenous HTT levels or the levels of a selection of other polyglutamine-containing proteins ( Fig. 10A and B) . However, we are aware of the limitations of this transgenic model, in which a human huntingtin fragment is expressed under the PrP promoter. Therefore, to further examine PMO pharmacokinetics, possible effects on behavior, and off-target effects, we examined the effect of three successive, low-dose ICV injections of CTG28 over the course of six months on the Hdh Q7/Q150 knock-in HD mouse model (Fig. 10C) . CTG28 was effective in selectively inhibiting mutant HTT expression in widely scattered brain regions two months after the last injection. We observed that CTG28 has a higher efficacy in the cortex than in the striatum, perhaps reflecting different PMO penetration into the two regions, or cell-type selectivity of response to CTG28. We also determined that CTG28 treatment attenuated the abnormal behavior displayed by Hdh Q7/Q150 knock-in mice on the tail suspension test. Unfortunately, only a limited behavioral analysis can be performed on Hdh Q7/Q150 mice, as they exhibit very little phenotype at twelve months of age (69, 70) . While we did not detect significant off-target effects of CTG28 (Fig. 10D) , it is important to note that the repeat length of repeat-containing genes is almost universally shorter than repeats in the orthologous human genes (65), so any repeat targeting strategy will require careful exploration of off-target effect in human tissue. The absence of loss of body weight relative to controls [a simple assay of systemic health commonly used to assess PMOs (75-77)]
following CTG28 injection provides additional evidence of the in vivo safety of PMOs (Fig. 10E ).
PMOs are uniquely amenable to modifications, and a range of changes could address issues such as the need to enhance their delivery across the blood-brain barrier (BBB) using less invasive delivery routes than ICV or brain parenchyma 
MATERIALS AND METHODS

Reagents and antibodies
Standard control PMO, custom made PMOs and Endo-Porter (in DMSO solution)
were obtained from Gene Tools, LLC (Philomath, OR). The sequence for each of the PMOs used in this study is given in Figure 1 . Taqman Assay IDs for real-time PCR Membranes were incubated with primary antibodies overnight at 4 o C. After washing with TBS-T, membranes were incubated with the corresponding secondary antibodies and protein bands were detected using the ECL Prime Western Blotting System (GE Healthcare, UK). Images were analyzed with ImageJ Software (NIH, http://rsbweb.nih.gov/ij/). Relative protein levels of TBP were obtained by normalizing TBP levels to that of histone H1, while β-actin was used as an internal control for other proteins.
RNA isolation and real-time PCR
Total RNA was isolated using TRIZOL reagent (Sigma-Aldrich), according to the manufacturer's manual. Total RNA was reverse-transcribed using random hexamer primers and SuperScript III reverse transcriptase (Life Technologies). The ABI 7900HT detection system (Applied Biosystems) was used for real-time PCR.
Gene-specific Taqman primers and probes (Applied Biosystems) were used to monitor the replication of PCR products. Human GUSB was selected as an internal control. Quantities of transcripts were obtained using the standard curve method and normalized to GUSB RNA levels. RNA expression levels were represented as ratio of the gene of interest to GUSB.
Caspase-3/7 activity assay Cells were treated with PMOs in 96 well plates and incubated with 100 µL/well of Caspase-Glo 3/7 reagent for 1 h at 37℃. Fluoroskan Ascent Microplate Fluorometer (Thermo Scientific, Waltham, MA) was used to quantify luminescence. Relative luminescence unit (RLU) measurements of all treated groups were normalized to that of the non-treated group.
LDH assay
Released LDH activity was measured according to the manufacturer's protocol (Roche, Berlin, Germany). Briefly, 50 µL of conditioned media from cell cultures were incubated with 50 µL of LDH assay buffer at room temperature for 20 minutes in the dark. The reaction mixture was stopped and the absorbance was read at 492 nm.
Fresh medium was also assayed as background and subtracted from each group to get relative LDH activity. Relative LDH activity of the non-treated control group was defined as 100, and all other groups were normalized to this value.
Immunofluorescence
Cells were seeded onto Poly D-Lysine-coated cover slips in a 24-well plate at 1×10 overnight, followed by washing and 1-hour incubation with a secondary antibody. All images were acquired using a Nikon Eclipse E400 epifluorescence microscope (Nikon, Tokyo, Japan) and MetaVue 4.6 software (Molecular Devices, Sunnyvale, CA).
ICV injection in HD mouse
The breeding and subsequent use of N171-82Q transgenic mice and Hdh previously freeze-dried PMO were resuspended in 2 µL saline to create a 6 mM injection solution, which was injected using a 2 µL Hamilton syringe over one minute.
After injection, the needle was withdrawn and skin was closed with cyanoacrylate glue. Post-surgical health was monitored until sufficient recovery was attained in respiration and mobility levels. 14 days after ICV injection, mice were killed by rapid decapitation and frozen brain region punches were taken in a cryostat. Total lysate of the frontal cortex was prepared from each mouse and used in western blot analysis.
Six-month-old Hdh Q7/Q150 knock-in mice were subject to the same injection protocol for three injections at six, eighth and tenths of age. The mice's body weight was measured weekly from the first injection. Two months after the last ICV injection, the mice were examined in the tail suspension test and then killed. The ipsilateral hemisphere of each mouse brain was dissected into the frontal cortex, striatum and cerebellum for western blot analysis.
Tail suspension test
The tail suspension test is a standard mouse behavioral phenotyping procedure that is 
Statistical analysis
Experiments were repeated at least three times. Data were presented as mean ± SD.
The results were analyzed using Student's t-test, one-way analysis of variance 
